PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: AN ENGLISH PAYER PERSPECTIVE

Journal article

Open access

Peer reviewed

C. Brown, A. Mayes, J. Schelfhout, Y. Jiang, M. Glover and E. Taymor

Value in health, Vol.21, pp.S451-S452

10/2018

Files and links (1)

url

https://doi.org/10.1016/j.jval.2018.09.2668View

Published (Version of record) Open

1 Record Views

Title: PSY93 - COST EFFECTIVENESS OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE IN ADULT CMV-SEROPOSITIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT: AN ENGLISH PAYER PERSPECTIVE
Creators: C. Brown - MSD (UK) Limited
A. Mayes - MSD (UK) Limited
J. Schelfhout - Merck & Co., Inc., Rahway, NJ, USA
Y. Jiang - MSD (UK) Limited
M. Glover - PHMR Ltd, London, UK
E. Taymor - MSD (UK) Limited
Publication Details: Value in health, Vol.21, pp.S451-S452
Publisher: Elsevier Inc; NEW YORK
Number of pages: 3
Publication Date: 10/2018
Identifiers: 991050250202346; WOS:000459985604342
Academic Unit: School of Biosciences
Language: English
Resource Type: Journal article